# Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

> **NCT05131477** · PHASE2 · COMPLETED · sponsor: **Kymab Limited** · enrollment: 390 (actual)

## Conditions studied

- Eczema
- Atopic Dermatitis

## Interventions

- **DRUG:** Amlitelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05131477
- **Lead sponsor:** Kymab Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2023-04-26
- **Final completion:** 2024-02-21
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131477, "Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05131477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*